BiotechTube

Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Brain Tumor

Conditions

Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm

Trial Timeline

Aug 8, 2019 → Jan 13, 2025

NCT ID
NCT04023669

About Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim

Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim is a phase 1 stage product being developed by Eli Lilly for Brain Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT04023669. Target conditions include Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory.

What happened to similar drugs?

5 of 18 similar drugs in Brain Tumor were approved

Approved (5) Terminated (2) Active (13)
✅ExenatideAstraZenecaApproved
✅RivastigmineNovartisApproved
✅Genotropin (PN-180,307) SomatropinPfizerApproved
✅Genotropin + PlaceboPfizerApproved
✅Dotarem® + Gadovist®/Gadavist®GuerbetApproved
🔄Nivolumab + TemozolomideOno PharmaceuticalPhase 3
🔄Nivolumab + TemozolomideOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04023669Phase 1Completed

Competing Products

20 competing products in Brain Tumor

See all competitors
ProductCompanyStageHype Score
Abemaciclib + Endocrine therapyEli LillyPhase 1/2
39
Duloxetine + Sugar pillEli LillyPhase 2
27
Neurosteroid enantiomerOragenicsPhase 2
32
Patritumab deruxtecanDaiichi SankyoPhase 2
27
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
29
Eribulin MesylateEisaiPhase 1
29
Pembrolizumab + LenvatinibEisaiPhase 2
42
Palonosetron (Aloxi) and DexamethasoneEisaiPhase 2
27
GLIADELEisaiPhase 2
35
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
40
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
40
abemaciclib + abemaciclibEli LillyPhase 2
39
JNJ-17299425Johnson & JohnsonPhase 2
27
ABT-888AbbViePhase 1
29
Veliparib + PlaceboAbbViePhase 2
35
Iressa (Gefitinib)AstraZenecaPhase 2
27
Trastuzumab deruxtecanAstraZenecaPhase 2
42
ExenatideAstraZenecaApproved
43
AZD5213AstraZenecaPhase 1
29
VorinostatMerckPhase 1
29